Testing a new drug for safety in prostate cancer patients
Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer
This study is looking at a new drug called (R)-9b to see if it's safe and how well it works for men with advanced prostate cancer that hasn't responded to other treatments, and it hopes to help boost the immune system to fight the cancer better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10978965 on NIH RePORTER |
What this research studies
This research investigates the safety and tolerability of a new drug called (R)-9b, designed to inhibit a specific protein (ACK1) that plays a role in prostate cancer progression. The study will involve patients with advanced prostate cancer who have not responded to standard treatments. Participants will receive the drug and be monitored for any side effects, as well as for its ability to activate the immune system against cancer cells. The research aims to provide insights into how this new treatment could improve outcomes for patients with resistant forms of prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those who have developed resistance to current therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that enhances the immune response against prostate cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promising results with similar approaches targeting immune modulation in cancer treatment, suggesting potential for success in this novel application.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Mahajan, Nupam P — Washington University
- Study coordinator: Mahajan, Nupam P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.